Prostaglandin E1 Therapy in Patients of Congenital Heart Disease With Pulmonary Atresia

The KITAKANTO Medical Journal
doi 10.2974/kmj1951.44.155
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Kitakanto Medical Society

Related search

Side Effects of Therapy With Prostaglandin E1 in Infants With Critical Congenital Heart Disease

Circulation
Cardiovascular MedicinePhysiologyCardiology
1981English

Formation of Biologically Active 13,14-Dihydro-Prostaglandin E1 During Intravenous Infusion of Prostaglandin E1 in Newborns With Ductus Arteriosus-Dependent Congenital Heart Disease.

British Journal of Clinical Pharmacology
Pharmacology
1992English

1152 Prostaglandin E1 Use in the Transfer of Infants With Suspected Duct Dependent Congenital Heart Disease

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2012English

Effects of Prostaglandin E1 Infusion in the Pre-Operative Management of Critical Congenital Heart Disease.

Tohoku Journal of Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
1985English

Emerging Therapy of Congenital Heart Disease Associated With Pulmonary Hypertension

Advances in Pulmonary Hypertension
2007English

Prevalence of Cerebral and Pulmonary Thrombosis in Patients With Cyanotic Congenital Heart Disease

Heart
Cardiovascular MedicineCardiology
2015English

Pacing Therapy in Pediatric and Congenital Heart Disease Patients

Circulation Journal
MedicineCardiovascular MedicineCardiology
2014English

Pulmonary Hypertension in Congenital Heart Disease

Future Cardiology
Molecular MedicineCardiovascular MedicineCardiology
2018English

Congenital Pulmonary Lymphangiectasia in Patient With Pulmonary Vein Stenosis/Atresia

Bratislava Medical Journal
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy